Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Scientific Officer | November 08, 2019 | November 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date November 08, 2019 · Filed November 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,061 |
Ending reported balance
After 2019-11-08 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-11-08 · Exercise / conversion · Acquired 14,698 · Balance 30,759 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Row 2 · 2019-11-08 · Exercise / conversion · Acquired 4,750 · Balance 35,509 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Row 3 · 2019-11-08 · Sale · Disposed 19,448 · Balance 16,061 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2022-06-05 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Exercise / conversion · Disposed 14,698 · Balance 0 F2: The stock options are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.37 · Expires 2023-03-05 | Direct | 20,250 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Exercise / conversion · Disposed 4,750 · Balance 20,250 F2: The stock options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: The stock options are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2019 Filed Nov 12, 2019 17:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,750 | $0.00 Strike: $25.37 | $0.00 |
DisclosureSEC source: 0001209191-19-056090 · doc4.xml · derivative · entry 5 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 4,750 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,698 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-19-056090 · doc4.xml · derivative · entry 4 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,698 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 19,448 | $45.00 | $875,160.00 |
DisclosureSEC source: 0001209191-19-056090 · doc4.xml · nonDerivative · entry 3 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,061 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 4,750 | $25.37 | $120,507.50 |
DisclosureSEC source: 0001209191-19-056090 · doc4.xml · nonDerivative · entry 2 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 14,698 | $10.81 | $158,885.38 |
DisclosureSEC source: 0001209191-19-056090 · doc4.xml · nonDerivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 17:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035126 · doc4.xml · derivative · entry 5 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-05 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 17:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035126 · doc4.xml · nonDerivative · entry 4 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,061 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 17:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,114 | $43.50 | $178,959.00 |
DisclosureSEC source: 0001209191-19-035126 · doc4.xml · nonDerivative · entry 3 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,061 F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 17:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,852 | $42.66 | $121,666.32 |
DisclosureSEC source: 0001209191-19-035126 · doc4.xml · nonDerivative · entry 2 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,175 F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 17:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,074 | $42.91 | $88,995.34 |
DisclosureSEC source: 0001209191-19-035126 · doc4.xml · nonDerivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,027 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-19-034738 · doc4.xml · derivative · entry 5 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,010 | $0.00 Strike: $10.52 | $0.00 |
DisclosureSEC source: 0001209191-19-034738 · doc4.xml · derivative · entry 4 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,010 shares Expires 2022-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 15,510 | $43.21 | $670,187.10 |
DisclosureSEC source: 0001209191-19-034738 · doc4.xml · nonDerivative · entry 3 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,101 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.14 to $43.49, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 12,500 | $10.81 | $135,125.00 |
DisclosureSEC source: 0001209191-19-034738 · doc4.xml · nonDerivative · entry 2 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,010 | $10.52 | $31,665.20 |
DisclosureSEC source: 0001209191-19-034738 · doc4.xml · nonDerivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 47,250 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038202 · doc4.xml · derivative · entry 2 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,250 Underlying: Common Stock · 47,250 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038202 · doc4.xml · nonDerivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,101 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2019, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:09 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,367 | $33.02 | $45,138.34 |
DisclosureSEC source: 0001209191-18-036184 · doc4.xml · nonDerivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,226 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 02, 2018 Filed May 4, 2018 18:51 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $34.38 | $0.00 |
DisclosureSEC source: 0001209191-18-028188 · doc4.xml · derivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-02 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040683 · doc4.xml · derivative · entry 2 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040683 · doc4.xml · nonDerivative · entry 1 Scranton Richard · CIK 0001709330 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,593 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.